Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

FIL10
91653
FIL2
90481
interpreted in the context of other clinical factors present in a given patient. Frequency of the
rs12979860 C allele varies across different racial and ethnic groups. The rs12979860 C variant is most
frequently present in individuals from East Asia (allele frequency >0.9) and least common in
individuals of African origin (allele frequency 0.2-0.5).(2) In a recent US-based study, the favorable CC
genotype was observed in 37% of Caucasians, 29% Hispanics, and 14% of African Americans tested.
The mechanism by which the IL28B genotype mediates response to pegylated-interferon and ribavirin
combination therapy among HCV genotype 1-infected individuals is not yet understood and is the
subject of intense ongoing research. The impact of the IL28B-related polymorphism on response rates
in patients infected with HCV genotypes other than genotype 1 is still being investigated.
Useful For: Predicting responsiveness of genotype 1 hepatitis C viral infections to combined
pegylated-interferon and ribavirin-based therapies This saliva-based test is especially useful for
establishing the IL28B genotype in patients who received a heterologous blood transfusion, in the
preceding 45 days (6 weeks) or allogeneic bone marrow transplants.
Interpretation: CC Genotype: An individual with IL28B-related rs12979860 CC genotype (ie, 2
copies of the C allele for the rs12979860 single-nucleotide polymorphism) responds more to
pegylated-interferon and ribavirin combination therapy. Patients with CC genotype also show more
spontaneous clearance of hepatitis C virus infection. CT Genotype: An individual carrying the
IL28B-related rs12979860 CT genotype is less likely to respond to pegylated-interferon and ribavirin
combination therapy. TT Genotype: An individual carrying the IL28B-related rs12979860 TT genotype is
less likely to respond to pegylated-interferon and ribavirin combination therapy.
Reference Values:
Not applicable
Clinical References: 1. Ge D, Fellay J, Thompson AJ, et al: Genetic variation in IL28B predicts
hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401 2. Thomas DL, Thio CL, Martin
MP, et al: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature
2009;461:798-801 3. Thompson AJ, Muir AJ, Sulkowski MS, et al: Interleukin-28B polymorphism
improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in
hepatitis C virus-1 patients. Gastroenterology 2010;139:120-129 4. Chalton MR, Thompson A, Veldt BJ,
et al: Interleukin-28B polymorphisms are associated with histological recurrence and treatment response
following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011;53:317-324
Interleukin-10 (IL-10), Serum
Reference Values:
Reference Range: